The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or ...

In conjunction with its better-than-expected sales growth in the second quarter, Tempus AI raised its sales outlook for this ...

Shares in health technology group Tempus AI ($TEM) raced 7% higher today after its Q2 revenues surged on cancer testing ...

In trading on the Nasdaq stock market as of 1:17 p.m. Central, Tempus' stock price was trading at $60.65, up 3.2% from the ...

Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday. The AI-focused precision medicine and patient ...

The firm's genomics revenues more than doubled year over year, while data and services revenue increased nearly 36 percent.

Tempus AI (NASDAQ:TEM) stock sees a 9% pre-market gain as the company raises its 2025 revenue outlook amid strong Q2 ...

Shares of Tempus AI climbed after the company narrowed its net loss and logged higher-than-expected revenue in the second quarter, boosted by what Chief Executive Eric Lefkofsky called a significant ...

Tempus AI (NASDAQ:TEM) surged 9% in premarket trading on Friday after the genetic testing company posted a ...

CHICAGO (AP) — CHICAGO (AP) — Tempus AI Inc. (TEM) on Friday reported a loss of $42.8 million in its second quarter. The Chicago-based company said it had a loss of 25 cents per share. Losses, ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended June 30, 2025.

Analysts expect the Chicago, Illinois-based company to report a quarterly loss at 25 cents per share, versus a year-ago loss ...